| 2015-04-27 |
1 |
|
-infringement of
United States Patent No. 6,878,703 (“the ’703 patent”) to enable Apotex to bring its…the
expiration of United States Patent No. 5,616,599 (“the ’599 patent”) and any applicable pediatric
… PATENT IN SUIT
15. On its face the ’703 patent entitled “Pharmaceutical…United States Patent and Trademark Office on April 12, 2005. A copy of the ’703
patent is attached as…States Patent and Trademark Office, Sankyo
Company, Limited is the assignee of the ’703 patent.
|
External link to document |
| 2015-09-15 |
38 |
|
Apotex seeks summary judgment that U.S. Patent No. 6,878,703 is not, will not, and
cannot be infringed…204261 because all of the claims of U.S. Patent No.
6,878,703 have been disclaimed.
Apotex’s Statement…2015
8 January 2016
1:15-cv-03695
830 Patent
None
District Court, N.D. Illinois |
External link to document |
| 2015-09-15 |
39 |
|
There is No Genuine Dispute.
U.S. Patent No. 6,878,703 issued on 12 April 2005, and it was assigned… granted for Apotex, declaring that U.S. Patent No. 6,878,703 is not, will not, and cannot be
infringed… B. No Infringement of US 6,878,703.
US 6,878,703 will not be infringed by the Apotex…Company, Limited disclaimed
every claim of US 6,878,703 on 11 July 2006. Ex. B.
Apotex has submitted…the infringement by others of any claim of US 6,878,703.
C. The Federal Circuit Decided There |
External link to document |
| 2016-01-08 |
66 |
|
United
States Patents Nos. 6,878,703 (the “703 patent”) and 5,616,599 (the “599 patent”) with the FDA…1) no patent information has been filed with the FDA, (2) the patent has expired, (3) the patent will
…infringed the ‘599
patent, and Mylan’s Paragraph IV certifications for that patent were thus converted…ANDA infringed on a patent, and that it should not be
considered until that patent expired). Mylan’s ANDAs…Paragraph IV
certifications as to the ‘703 patent because that patent, although disclaimed, remains listed |
External link to document |
